EX-12.1 4 y17762exv12w1.txt EX-12.1: STATEMENT RE: COMPUTATION OF RATIO OF EARNINGS TO COMBINED FIXED CHARGES EXHIBIT 12.1 REGENERON PHARMACEUTICALS, INC. COMPUTATION OF RATIO OF EARNINGS TO COMBINED FIXED CHARGES (Dollars in thousands)
Years ended December 31, -------------------------------------------------------- 2001 2002 2003 2004 2005 -------- --------- --------- -------- -------- Earnings: Income (loss) from continuing operations before income (loss) from equity investee $(75,178) $(124,350) $(107,395) $ 41,565 $(95,456) Fixed charges 3,888 13,685 14,108 14,060 13,687 Amortization of capitalized interest -- -- 33 78 78 Interest capitalized -- (222) (276) -- -- -------------------------------------------------------- Adjusted earnings $(71,290) $(110,887) $(93,530) $ 55,703 $(81,691) ======================================================== Fixed charges: Interest expense $ 2,657 $ 11,859 $ 11,932 $ 12,175 $ 12,046 Interest capitalized -- 222 276 -- -- Assumed interest component of rental charges 1,231 1,604 1,900 1,885 1,641 -------------------------------------------------------- Total fixed charges $ 3,888 $ 13,685 $ 14,108 $ 14,060 $ 13,687 ======================================================== Ratio of earnings to fixed charges (A) (A) (A) 3.96 (A) (A) Due to the registrant's losses for the years ended December 31, 2001, 2002, 2003, and 2005, the ratio coverage was less than 1:1. To achieve a coverage ratio of 1:1, the registrant must generate additional earnings of the amounts shown in the table below.
Years ended December 31, --------------------------------------------- 2001 2002 2003 2005 -------- --------- --------- -------- Coverage deficiency $75,178 $124,572 $107,638 $95,378